SCHEMBL623886

SCHEMBL623886

CC(C)=CCc1ccccc1-c1cc(=O)c2ccccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.57
AKR1C2 P52895 1/20 0.57
AKR1C1 Q04828 1/20 0.57
HPGD P15428 6/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 4/20 0.53
CYP3A4 P08684 5/20 0.53
KDM4E B2RXH2 4/20 0.53
MEN1 O00255 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
KMT2A Q03164 3/20 0.53
TP53 P04637 3/20 0.53
MAPT P10636 3/20 0.53
ALOX15 P16050 3/20 0.53
CYP2D6 P10635 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
HSD17B10 Q99714 2/20 0.53
ALOX12 P18054 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11035644 0.82 HPGD (0.63) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL8630307 0.81 HPGD (0.55) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL29149152 0.80 CYP19A1 (0.61) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL15899626 0.78 CYP3A4 (0.56) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL15360894 0.78 VKORC1 (0.57) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL10800023 0.75 HPGD (0.55) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL10800581 0.74 HPGD (0.53) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL7141873 0.73 CYP3A4 (0.61) HPGDSMN1; SMN2NPC1RAB9ACYP3A4
SCHEMBL3205778 0.73 HPGD (0.67) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2
SCHEMBL312255 0.73 AKR1C3 (1.00) AKR1C3AKR1C2AKR1C1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114796194-A Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor 澳门大学 2022-07-29 CN claimed
CN-119258055-A Composition for inhibiting oral pathogenic bacteria and application thereof 大连医科大学附属第二医院 2025-01-07 CN disclosed
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH UNIGEN, INC. (US) 2023-06-22 US disclosed
CN-112851615-B Preparation of isopentenyl flavone and application of isopentenyl flavone as medicine for treating cervical cancer 厦门大学 2023-04-07 CN disclosed
CN-112851615-B Preparation of isopentenyl flavone and application of isopentenyl flavone as medicine for treating cervical cancer 厦门大学 2023-04-07 CN disclosed
CN-112552309-B Psoralen benzene sulfonate derivative and application thereof 中国科学院新疆理化技术研究所 2023-03-14 CN disclosed
CN-115650942-A Method for extracting, separating and purifying 8-isopentenyl naringenin from hops 长沙市惠瑞生物科技有限公司 2023-01-31 CN disclosed
CN-113004353-B Cyclocarya paliurus extract and application thereof 中南大学 2022-08-19 CN disclosed
CN-113150048-B Cyclocarya paliurus extract and application thereof in resisting rheumatoid arthritis 中南大学 2022-08-19 CN disclosed
CN-114796194-A Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor 澳门大学 2022-07-29 CN disclosed
EP-1453827-A4 METHODS FOR PREPARING AN ESTROGENIC PREPARATION AND ISOLATED ESTROGENIC COMPOUNDS FROM A PLANT AND USES THEREOF UNIV SINGAPORE (SG) 2005-02-23 EP disclosed
EP-1453827-A1 METHODS FOR PREPARING AN ESTROGENIC PREPARATION AND ISOLATED ESTROGENIC COMPOUNDS FROM A PLANT AND USES THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2004-09-08 EP disclosed
US-6750248-B2 FLAVONE ANALOGS MODULATE ESTROGEN RECEPTORS; USEFUL IN TREATING MENOPAUSE SYMPTOMS AND ESTROGEN-DEPENDENT CANCERS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2004-06-15 US disclosed
WO-2003040134-A9 METHODS FOR PREPARING AN ESTROGENIC PREPARATION AND ISOLATED ESTROGENIC COMPOUNDS FROM A PLANT AND USES THEREOF UNIV SINGAPORE (SG) 2004-03-25 WO disclosed
US-20030190375-A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts DR. WILLMAR SCHWABE GMBH & CO. (DE) 2003-10-09 US disclosed
US-20030180394-A1 Extracts from sophora species, method for producing the same and their use DR. WILLMAR SCHWABE GMBH & CO. (DE) 2003-09-25 US disclosed
US-20030170292-A1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof NATIONAL UNIVERSITY OF SINGAPORE 2003-09-11 US disclosed
WO-2003040134-A1 METHODS FOR PREPARING AN ESTROGENIC PREPARATION AND ISOLATED ESTROGENIC COMPOUNDS FROM A PLANT AND USES THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2003-05-15 WO disclosed
WO-2002051426-A2 COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION, ENHANCING SEXUAL FUNCTION, INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS BRASWELL A GLENN (US) 2002-07-04 WO disclosed
US-6071883-A ADMINISTERING FLAVONE DERIVATIVE AS AN IMMUNOSUPPRESSANT TO THE RECIPIENT IN NEED OF A GRAFT REJECTION PREVENTION OR SUPPRESSION AFTER ALLOGRAFT ORGAN TRANSPLANT CHEN HUIFANG (CA) 2000-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030190375-A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts SHBG, CYP19A1, HSD17B11 AKR1C3 238/4885AKR1C2 411/4885AKR1C1 465/4885
US-20030170292-A1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof ESR1, ESR2, GPER1 AKR1C3 719/4885AKR1C2 547/4885AKR1C1 782/4885
US-20030180394-A1 Extracts from sophora species, method for producing the same and their use CYP19A1, SHBG, CYP17A1 AKR1C3 1730/4885AKR1C2 1821/4885AKR1C1 2075/4885
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH PTGES, PTGES3, PTGES2 AKR1C3 2167/4885AKR1C2 2748/4885AKR1C1 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.